Related Experiment Video
Updated: Jun 21, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
[Mass screening prostate cancer and clinical comparison]
Rui Zhao1, Xiang-bo Kong, Mu-chun Zhang
1Department of Urology, China-Japan Union Hospital of Jilin University, Changchun 130021, China.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]
|July 21, 2009
Summary
Mass screening for prostate cancer helps detect early-stage, asymptomatic cases. This approach identifies more localized tumors and benefits patients through timely intervention.
Area of Science:
- Urology
- Oncology
- Public Health
Context:
- Prostate cancer screening remains a critical public health initiative.
- Understanding the characteristics of prostate cancer detected through mass screening versus clinical diagnosis is essential for optimizing detection strategies.
Purpose:
- To compare the clinical features of prostate cancer in patients identified through mass screening versus those diagnosed clinically.
- To evaluate the effectiveness of mass screening in detecting early-stage prostate cancer.
Summary:
- A study analyzed 441 prostate cancer cases (319 from mass screening, 122 from clinical diagnosis) between 2000-2008.
- Mass screening identified a higher proportion of early-stage (T1-2) and moderately differentiated prostate cancers compared to clinical diagnosis.
- Patients from mass screening showed lower rates of advanced disease (T3-4, metastasis) and higher rates of radical prostatectomy.
Impact:
- Mass screening facilitates the detection of asymptomatic, early-stage prostate cancer, leading to potentially better patient outcomes.
- The findings support the clinical value of general investigations for prostate cancer in identifying cases at an earlier, more treatable stage.
